[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Nitric Oxide Synthase Brain - Pipeline Review, H2 2019

December 2019 | 43 pages | ID: N6CA664BCB86EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Nitric Oxide Synthase Brain - Pipeline Review, H2 2019

SUMMARY

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Nitric oxide synthase 1 or NOS1 is an enzyme encoded by the NOS1 gene. It produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter.

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Infectious Disease, Oncology and Respiratory which include indications Dyskinesia, Parkinson's Disease, Neurodegenerative Diseases, Migraine, Visceral Pain, Bacterial Infections, Bladder Pain, Cardiac Arrest, Cerebral Palsy, Hypoxia, Melanoma, Musculoskeletal Pain, Neuroinflammation, Post-Operative Pain and Post-Traumatic Stress Disorder (PTSD).

The latest report Nitric Oxide Synthase Brain - Pipeline Review, H2 2019, outlays comprehensive information on the Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)
  • The report reviews Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Overview
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Companies Involved in Therapeutics Development
Eli Lilly and Co
NeurAxon Pharma Inc
Neurophyxia BV
SalubRx Therapeutics Inc
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Drug Profiles
2-Iminobiotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-87201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-462 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-613 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBX-774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOS for Neurodegenerative Diseases and Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Dormant Products
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Product Development Milestones
Featured News & Press Releases
Aug 31, 2015: Formulation patent granted in US, China, Australia and New Zealand
Jul 31, 2015: Neurophyxia Provides Update on Phase II study of 2-IB
Sep 30, 2014: Neurophyxia Provides Update on Phase II Clinical Study of 2-Iminobiotin
Oct 15, 2012: Indiana University Scientists Identify New Compound That Could Prevent Post-Traumatic Stress Disorder
Feb 29, 2012: Neurophyxia Provides Update on 2-Iminobiotin
Jun 30, 2011: Neurophyxia Announces Completion of Phase I Study
Oct 31, 2010: NeurAxon Reports NXN-188 Phase II Data Demonstrates Efficacy In Acute Migraine
Jun 30, 2010: Neurophyxia Provides Update on Cinical Study of 2-Iminobiotin
Jan 31, 2010: Neurophyxia Receives Orphan Drug Designation in Europe for 2-IB
Feb 28, 2009: Neurophyxia Receives Orphan Drug Designation from FDA for 2-Iminobiotin
Oct 27, 2008: NeurAxon's NXN-188 Names One Of 10 Most Promising Neuroscience Projects
Sep 30, 2008: Neurophyxia Provides Update on Pre-Cinical Study of 2-Iminobiotin
Sep 05, 2008: NeurAxon’s NXN-188 Demonstrates Pain Relief In Migraine with Aura
Aug 14, 2007: NeurAxon Announces Positive Phase 1 Trial Data On NXN-188 For Migraine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by NeurAxon Pharma Inc, H2 2019
Pipeline by Neurophyxia BV, H2 2019
Pipeline by SalubRx Therapeutics Inc, H2 2019
Dormant Projects, H2 2019

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019

COMPANIES MENTIONED

Eli Lilly and Co
NeurAxon Pharma Inc
Neurophyxia BV
SalubRx Therapeutics Inc


More Publications